Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):586-9.

2.

Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):65-8.

3.

HIV preexposure prophylaxis: new data and potential use.

Celum CL.

Top Antivir Med. 2011 Dec;19(5):181-5.

4.

Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.

Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM; Partners PrEP Study Team..

JAMA. 2014 Jul 23-30;312(4):362-71. doi: 10.1001/jama.2014.8735.

5.

Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):463-5.

6.

Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.

Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM; Partners PrEP Study Team..

Ann Intern Med. 2014 Jul 1;161(1):11-9. doi: 10.7326/M13-2471.

PMID:
24979446
7.

[HIV preexposure prophylaxis].

Olczak A, Grabczewska E.

Przegl Epidemiol. 2012;66(1):79-82. Review. Polish.

8.

Considerations regarding antiretroviral chemoprophylaxis in MSM.

Poynten IM, Zablotska I, Grulich AE.

Curr Opin HIV AIDS. 2012 Nov;7(6):549-56. doi: 10.1097/COH.0b013e3283582c71. Review.

PMID:
22918448
9.

Emtricitabine/tenofovir disoproxil fumarate.

[No authors listed]

Drugs R D. 2004;5(3):160-1. Review.

PMID:
15139777
10.

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT; TDF2 Study Group..

N Engl J Med. 2012 Aug 2;367(5):423-34. doi: 10.1056/NEJMoa1110711.

11.

Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.

Myers GM, Mayer KH.

AIDS Patient Care STDS. 2011 Feb;25(2):63-71. doi: 10.1089/apc.2010.0222. Review.

PMID:
21284497
12.

Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.

Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, Mujugira A, Tappero J, Kahle EM, Thomas KK, Baeten JM; Partners PrEP Study Team..

AIDS. 2013 Aug 24;27(13):2155-60. doi: 10.1097/QAD.0b013e3283629037.

13.

Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.

Plosker GL.

Drugs. 2013 Mar;73(3):279-91. doi: 10.1007/s40265-013-0024-4. Review.

PMID:
23444256
14.

Pre-exposure chemoprophylaxis of HIV infection: quo vadis?

Clercq ED.

Biochem Pharmacol. 2012 Mar 1;83(5):567-73. doi: 10.1016/j.bcp.2011.10.016.

PMID:
22067069
15.

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C; Partners PrEP Study Team..

N Engl J Med. 2012 Aug 2;367(5):399-410. doi: 10.1056/NEJMoa1108524.

16.
17.

Preexposure prophylaxis for HIV infection among African women.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D; FEM-PrEP Study Group..

N Engl J Med. 2012 Aug 2;367(5):411-22. doi: 10.1056/NEJMoa1202614.

18.

Systemic preexposure prophylaxis for human immunodeficiency virus infection.

Romanelli F, Murphy B.

Pharmacotherapy. 2010 Oct;30(10):1021-30. doi: 10.1592/phco.30.10.1021. Review.

PMID:
20874040
19.

No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.

Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant RM.

PLoS One. 2013 Dec 18;8(12):e81997. doi: 10.1371/journal.pone.0081997.

20.

Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.

Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, Chariyalertsak S, Fernandez T, Grant RM; iPrEx Study Team..

Clin Infect Dis. 2014 Oct;59(7):1020-6. doi: 10.1093/cid/ciu450.

Items per page

Supplemental Content

Support Center